Drugs / [13N]NH3
[13N]NH3
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05583721 Background | Oct 2023 → Sep 2027 expected | sickle cell disease | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [13N]NH3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05583721 ↗ |
| Known as | ((sup 13)n)ammonia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1160819 ↗ |
| Known as | Ammonia (13n) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1160819 ↗ |
| Known as | Ammonia N 13 | “Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.” NCT05583721 ↗ |
| Known as | Ammonia-(sup 13)n | ChEMBL registry synonym — accepted as the source's own label CHEMBL1160819 ↗ |
| Modality | Small molecule | — CHEMBL1160819 ↗ |
| Route | Intravenous | “will be given per intravenous (IV) injection” NCT05583721 ↗ |